Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies

[1]  A. Tichelli,et al.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. , 2010, Blood.

[2]  A. Jankowska,et al.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. , 2010, Blood.

[3]  A. Kohlmann,et al.  AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions , 2010, Leukemia.

[4]  D. Birnbaum,et al.  Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias , 2010, Leukemia.

[5]  O. Abdel-Wahab,et al.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.

[6]  M. McDevitt,et al.  Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[8]  M. Carroll,et al.  A common genetic mechanism in malignant bone marrow diseases. , 2009, The New England journal of medicine.

[9]  D. Birnbaum,et al.  TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia , 2009, Haematologica.

[10]  A. Kohlmann,et al.  AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions. , 2009 .

[11]  A. Kohlmann,et al.  Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS . , 2009 .

[12]  J. Duyster,et al.  E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. , 2009, Blood.

[13]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[14]  M. Loh,et al.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.

[15]  G. Mufti,et al.  Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Vainchenker,et al.  Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. , 2009, Blood.

[17]  S. Ogawa,et al.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.

[18]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[19]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[20]  C. Mullighan.  TET2 mutations in myelodysplasia and myeloid malignancies , 2009, Nature Genetics.

[21]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[22]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1 , 2009, Science.

[23]  W. Hiddemann,et al.  CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes , 2009, Clinical Cancer Research.

[24]  D. Gilliland,et al.  Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.

[25]  D. Gilliland,et al.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.

[26]  R. Levine,et al.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. , 2009, Blood.

[27]  M. McDevitt,et al.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.

[28]  A. Hall,et al.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.

[29]  T. Haferlach,et al.  RUNX1 Mutations Play a Major Role in the Progression of MDS to S-AML Following MDS: A Genetic and Cytogenetic Analysis of Sequential Samples , 2008 .

[30]  B. Löwenberg,et al.  Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias , 2008, Haematologica.

[31]  M. Caligiuri,et al.  MicroRNA expression in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[32]  M. Cazzola,et al.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.

[33]  D. Christiansen,et al.  Genetics of therapy-related myelodysplasia and acute myeloid leukemia , 2008, Leukemia.

[34]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[35]  S. Fröhling,et al.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.

[36]  M. Caligiuri,et al.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. , 2007, Blood.

[37]  Chunaram Choudhary,et al.  Flt3-dependent transformation by inactivating c-Cbl mutations in AML. , 2007, Blood.

[38]  T. Haferlach,et al.  A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. , 2007, Haematologica.

[39]  D. Gilliland,et al.  JAK-2 mutations and their relevance to myeloproliferative disease , 2007, Current opinion in hematology.

[40]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[41]  T. Kyo,et al.  Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations , 2006, Leukemia.

[42]  A. Tefferi,et al.  JAK2 mutations in myeloproliferative disorders. , 2005, The New England journal of medicine.

[43]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[44]  M. Andersen,et al.  Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. , 2004, Blood.

[45]  Jen-Fen Fu,et al.  Identification of CBL, a proto‐oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[46]  S. Mathew,et al.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.

[47]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[48]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[49]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[50]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[51]  C. Bloomfield,et al.  Long‐term survival of patients with acute myeloid leukemia , 1997, Cancer.

[52]  W. Langdon,et al.  Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. , 1994, The EMBO journal.

[53]  C. Bloomfield,et al.  Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. , 1994, Cancer genetics and cytogenetics.

[54]  O. Bernard,et al.  Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias , 2010, Leukemia.

[55]  D. Gilliland,et al.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.

[56]  T-Cell Lymphoma.  47th Annual Meeting of the American Society of Hematology Atlanta, GA. , 2006, Clinical lymphoma & myeloma.

[57]  Y. Akao,et al.  Relationship of the human protooncogene CBL2 on 11q23 to the t(4;11), t(11;22), and t(11;14) breakpoints. , 1991, Cytogenetics and cell genetics.